Metastatic breast cancer trials in Malaysia

In Malaysia 5 Also abroad 610

5 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Where
Bandar Puncak Alam, Johor Bahru, Kuala Lumpur, Kuala Selangor, Malacca
Age
18 years and over
People
788 worldwide
Run by
AstraZeneca
See details and how to joinNCT06380751 · EU 2023-504180-16-00
Phase 1Taking people
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Where
George Town, Kuala Lumpur, Kuching, Putrajaya
Age
18 years and over
People
433 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06120283 · EU 2023-506888-34-00
Phase 3Taking people
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Where
Johor Bahru, Kuala Lumpur, Kuching
Age
18 years and over
People
1,200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06312176 · EU 2023-504918-29-00
Phase 3Taking people
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Where
George Town, Kota Bharu, Kuala Lumpur, Kuching, Petaling Jaya, Putrajaya
Age
18 years and over
People
1,180 worldwide
Run by
Celcuity Inc
See details and how to joinNCT06757634 · EU 2024-518933-28-01
Phase 3Taking people
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Where
George Town, Ipoh, Kota Kinabalu, Kuala Lumpur, Kuching, Petaling Jaya, Putrajaya
Age
18 years and over
People
1,000 worldwide
Run by
Olema Pharmaceuticals, Inc.
See details and how to joinNCT07085767 · EU 2025-522873-12-00